- Of Astrology and Access: Public Hearings At FDA Juxtapose Old Cries of Access With Those of Integrity, Accountability
- Mad, Mad Science: Improved Clinical Outcomes Wrought By Immunosuppressive Medicine and Second-Rate Immune Responses – Where Will It All End?
- The KS Project Report: Research Paper Details Advances, Obstacles In The Treatment of Kaposi’s Sarcoma
- Feet to the Fire: ACTG Investigators Scramble to Convince Industry They Can Produce
- Inter-Company Cahoots: ICC’s Brainchild Designed to Show Every Drug and Every Combination a Success. Who Could Complain About That?
- Stavudine for Everyone: Accelerated Approval Guidelines Expedite Bristol’s Launch of New Nucleoside — In the Absence of Any Proof That It Works
- Lesion Liberation Unlikely: KS Proves Formidable Foe As Angiogenesis Inhibitors and Stealth Chemotherapy Fall Short of Expectations
- Protease Quandary: One Company’s Search for an Effective Antiviral Contrasts Another’s Scramble for the Easy Money
- Vexed Virologists: Study After Study, Antiretroviral Analyses Confound More Than They Clarify